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Abstract
Background: Development of metastases and drug resistance are still a challenge for a successful systemic
treatment in breast cancer (BC) patients. One of the mechanisms that confer metastatic properties to the cell relies
in the epithelial-to-mesenchymal transition (EMT). Moreover, both EMT and metastasis are partly modulated
through epigenetic mechanisms, by repression or induction of specific related genes.
Methods: We applied shRNAs and drug targeting approaches in BC cell lines and metastatic patient-derived
xenograft (PDX) models to inhibit WDR5, the core subunit of histone H3 K4 methyltransferase complexes, and
evaluate its role in metastasis regulation.
Result: We report that WDR5 is crucial in regulating tumorigenesis and metastasis spreading during BC progression.
In particular, WDR5 loss reduces the metastatic properties of the cells by reverting the mesenchymal phenotype of
triple negative- and luminal B-derived cells, thus inducing an epithelial trait. We also suggest that this regulation is
mediated by TGFβ1, implying a prominent role of WDR5 in driving EMT through TGFβ1 activation. Moreover, such
EMT reversion can be induced by drug targeting of WDR5 as well, leading to BC cell sensitization to chemotherapy
and enhancement of paclitaxel-dependent effects.
Conclusions: We suggest that WDR5 inhibition could be a promising pharmacologic approach to reduce cell
migration, revert EMT, and block metastasis formation in BC, thus overcoming resistance to standard treatments.
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Background
Despite recent advances in breast cancer (BC) treatment,
women frequently develop resistance to endocrine and
chemotherapies and die of metastasis [1] so that, for
these patients, new treatment strategies are mandatory.
The reversion of epithelial-to-mesenchymal transition
(EMT) through re-differentiation of cancer cells repre-
sents a potential therapeutic challenge to ameliorate
patients’ prognosis [2, 3]. The EMT is a well-defined
developmental program adopted by tumor cells during
the metastatic cascade to gain migratory ability and
reach distant organs, losing epithelial cell adhesion and
cell-cell contacts, while undergoing cell shape remodel-
ing and cytoskeleton rearrangement [4]. Concurrently,
the expression of epithelial markers is inhibited, in favor
of an increase in the expression of the mesenchymal
genes [5]. The epithelial and mesenchymal states repre-
sent two opposite cellular phenotypes that the cells
reach going through several intermediary phases [6].
During EMT, changes in gene expression are crucial for
this process to occur.
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The transforming growth factor β1 (TGFβ1) signaling
pathway is involved in a plethora of events regulating
EMT. TGFβ1 is secreted by tumor cells as well as by
cells of the surrounding stroma, and is crucial in the
regulation of distinct processes, as cytoskeleton
organization, survival, cell migration, and invasion [7].
TGFβ1 signaling may control EMT and metastasis by
sustaining the epigenetic machinery through the DNA
binding activity of DNMT1 [8] or the histone
methylation-coupled transcriptional activation or repres-
sion of PRMT5-MEP50 axis [9]. Furthermore, numerous
epigenetic modifiers (i.e., HDACs, LSD1, SET8, PRC1/2,
PRMT7, and BRG1) seem to give a great contribution to
such a modulation since histone modifications (acetyl-
ation/deacetylation and methylation/demethylation) are
implicated in either inducing or repressing specific sets
of EMT-related genes (SNAI1/2, TWIST1/2 and ZEB1/
2) [10, 11].
WDR5 is a WD40 repeat protein that recognizes the
histone H3 amino-terminal tail and is essential for lysine
4 (H3K4) methylation [12]. A large body of evidence
supports the pivotal role of WDR5 in tumor growth and
proliferation [13–18], differentiation [19, 20], and metas-
tasis [21–23], and suggests that its expression is prog-
nostic in different tumor types [13, 15, 24–27].
Moreover, WDR5 binds the mesenchymal gene pro-
moter and transcriptionally regulates N-cadherin in BC
upon hypoxia treatment [28], ZNF407 in colorectal can-
cer [23], HOXA9 in prostate cancer [22], and SNAIL1
and VIMENTIN in lung tumor cells [9], leading to
EMT. Despite its proven involvement in EMT, a direct
interplay of WDR5 and TGFβ1 in activating this process
in BC remains elusive.
Here, we demonstrate that WDR5 is involved in EMT
and metastasis in BC and that its inhibition, by reducing
the migratory and mesenchymal phenotype, drives the
cells toward an epithelial-like status. Our data indicate a
direct regulation of WDR5 on the TGFβ1 pathway.
Moreover, we suggest that WDR5 inhibition could be
used as a therapeutic approach in Triple Negative (TN)
and Luminal B (LB) metastatic breast cancer and that its
combination with chemotherapy may be advantageous
for treatment of chemo-resistant patients.
Materials and methods
PDX tissue bank generation
Patients enrolled in the study were selected on the basis
of highly aggressive metastatic disease diagnoses (Lu-
minal B and Triple Negative subtypes) and resistance to
different lines of therapy. Biopsies from liver and lung
were transplanted in Matrigel (Corning #356231) ortho-
topically in the fourth mammary gland of female NSG
mice, as previously described [29]. Tumors were moni-
tored weekly and serially passaged in NSG after tissue
digestion (see “PDX culture”). Tumors were character-
ized by IHC on the basis of the prognostic clinical
markers, i.e., estrogen, progesterone, HER2, and Ki67, by
pathologists and compared to patient tumors. Positive
staining is expressed as percentage.
Animals
Non-obese diabetic/severe combined immunodeficiency
(NOD/SCID) mice were purchased from Harlan Labora-
tories. NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice
were purchased from Charles River. Only female mice
6–12 weeks old (15–20 g weight) were used for experi-
mental procedures.
Ethic statements
Investigations have been conducted in accordance with
the ethical standards and according to National and Inter-
national guidelines. In vivo studies were performed after
approval from our fully authorized animal facility, notifi-
cation of the experiments to the Ministry of Health (as
required by the Italian Law) (IACUCs N° 757/2015, 1246/
2015 and 327/2016) and in accordance to EU directive
2010/63. Human tissue biopsies were collected from
patients whose informed consent was obtained in writing
according to the policies of the Ethics Committee of the
European Institute of Oncology and regulations of Italian
Ministry of Health. The studies were conducted in full
compliance with the Declaration of Helsinki.
PDX culture
PDX tumors were dissociated by enzymatic and mech-
anical digestion (Miltenyi Biotec), and cells were plated
to obtain short-term cultures. PDX cells were main-
tained in DMEM/F12 (1:1, Lonza/Gibco) supplemented
with 10% fetal bovine serum (FBS) (HyClone, GE
Healthcare Life Science), 10 mM HEPES (Sigma), 5 μg/
mL insulin (Roche), 0.5 μg/mL hydrocortisone (Sigma),
10 ng/mL epidermal growth factor (EGF; Tebu-Bio), and
50 ng/mL Cholera Toxin (Sigma).
Cell lines
Experiments were performed in MCF10DCIS.com (from
Wayne State University, 5057 Woodward Avenue, De-
troit, Michigan), SUM149PT (from Asterand), HCC1428
(from ATCC), MDAMB468 (from CLS), ZR751 (from
ATCC), and MDA-MB-231 and MCF10A (both from
NIH Institute). Cell lines were maintained in their re-
spective media as recommended by suppliers. Cell line
authentication was performed in house by Gene Print 10
System every 6 months (Promega). All cell lines were
tested for mycoplasma and resulted negative.
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In vivo study
PDXs, MCF10DCIS.com, SUM149PT, HCC1428, MDAMB
468, and ZR751 were infected with control shRNA (shLuc)
and two pooled shWDR5. 2 × 105 infected cells were ortho-
topically injected into the fourth mammary gland of three to
nine mice (PDXs cells, SUM149PT, HCC1428, MDAMB
468, ZR751 in NSG mice; MCF10DCIS.com in NOD/SCID),
according to the experimental setting. Tumor volume was
calculated using this formula: V = L× l2/2 (L length; l width).
MDA-MB-231 cells were double transfected to express lucif-
erase (Addgene 17477) and to silence a neutral control
(SCR) or WDR5. Then 2 × 105 cells were transplanted in the
fourth mammary gland of 12 NSG mice per group. The
mice were monitored for primary tumor growth. For metas-
tasis experiments, when a volume of about 0.5 cm3 was
reached, tumors were excised and mice monitored weekly
for metastasis formation. Luciferase expression was assessed
by bioluminescence imaging (IVIS Lumina Imaging System -
PerkinElmer) and mice were sacrificed when lungs or axil-
lary lymph nodes resulted positive to luminescence. Lumi-
nescence was quantified by using Living Image software and
expressed as radiance in photons of the region of interest.
In vitro study
Proliferation, FBS-directed migration on Boyden cham-
ber, wound healing, and time-lapse live cell random mi-
gration assays were performed as described in
Additional file 3: Supplementary Methods.
Immunofluorescence
MCF10DCIS.com or MDA-MB-231 cells, infected to si-
lence WDR5 or treated by drugs, were plated on slides
and allowed to attach overnight. Next day, cells were
fixed with 4% paraformaldehyde for 10 min, perme-
abilized with 0.01% Triton-X, and blocked for 1 h with
2% bovine serum albumin. The antibodies against the
following protein were used: FITC-labeled Phalloidin
(P5282), Vimentin [V9] (ab8069), CDH2 [5D5]
(ab98952), CDH1 (24E10), SNAI2 (C19G7) and SNAI1
(C15D3), and α-Tubulin (T9026). Slides were then coun-
terstained with 4′,6-diamidino-2-phenylindole (DAPI)
for nuclei labelling and mounted on glass slides with
Mowiol. Images were collected by motorized Olympus
fluorescence microscope at × 40 magnification.
Adhesion assay
For adhesion assay, 2 × 104 shLuc and shWDR5 MCF1
0DCIS.com cells were plated onto different extracellular
matrices (collagen—CL, laminin—LM, fibronectin—FN,
matrigel—MG). After 1.5 h, cells were fixed and stained
with 0.5% Crystal Violet. Three images per well were ac-
quired, and cell number and area were quantified by using
ImageJ software by manually delineating the edges of
selected cells (a total of 30 measurements per group) and
recording the circularity value.
Western blot
PDX cells and other BC cell lines were lysed in RIPA
buffer and processed, as previously described [30].
Membranes were probed with antibodies reported in
Additional file 3: Supplementary Method. Images were
cropped at specific protein band of interest to improve
the clarity of data presentation.
Survival and expression analysis
Association between WDR5 expression and metastasis-
free survival (MFS) in 295 breast cancer patients was cal-
culated using PROGgene V2 software on NKI publicly
available data sets [31]. MFS were represented by Kaplan-
Meier functions, and cohorts were divided at the median
of gene expression. Statistic comparison between high and
low expression groups was performed using log-rank test.
Association between WDR5 silencing and survival in mice
was calculated by using GraphPad Prism 5.0, and significa-
tive differences among groups were calculated by using
log-rank test. Differences were considered significant at
P < 0.05. Analysis on TCGA data set of breast cancer
patients was performed by using publicly available data in
cBioportal for Cancer Genomics by considering expres-
sion values of genes from RNA-seq. Overexpression was
considered for z-score ≥ + 2. Co-occurrence of expression
of each gene and WDR5 was represented by P values, cal-
culated by the Fisher exact test.
Drug treatment
MDA-MB-231 and MCF10DCIS.com cells were treated
with a single exposure for 3 days of OICR-9429 (MD
Anderson Cancer Center - Texas) at a final concentra-
tion of 1 μM–5 μM–10 μM or 20 μM for 3 days and then
plated for migration assay. LY2157299 (galunisertib)
(MCE, HY-13226) was added by a single administration
for 3 days at final concentration of 10 μM. Short-term
in vitro growth inhibition by drugs in PDXs and MDA-
MB-231 cells was assessed by Cell Titer Glo (Promega).
Briefly, PDX cells (obtained from third passage in mice)
were thawed, plated in 2D cultures in 96 wells (5000
cells per well), and treated for 3 days by a single expos-
ure to vehicle or concentrations of the following drugs:
paclitaxel (1 nM–5 μM–10 nM), OICR-9429 20 μM, or
galunisertib 10 μM alone or in combination. MDA-MB-
231 cells (2000 cells per well) were treated for 3 days
with paclitaxel (10 nM), OICR-9429 (20 μM), or galuni-
sertib (10 μM) alone or in combination. The inhibition
of viability is indicated as a percent over control cell
viability of the aforementioned drugs (calculated using
GraphPad Prism software).
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RNA sequencing
Total RNA was extracted from shLuc and shWDR5
MCF10DCIS.com or PDX cells by using the Maxwell
16LEV simply RNA tissue kit. mRNA purification and
NGS libraries were obtained following Illumina instruc-
tion (TruSeq RNA Sample Preparation). Bioinformatic
analysis is fully described in Additional file 3: Supple-
mentary Methods.
ChIP sequencing
ChIP lysates were generated from 10–15 × 106 cells as
reported previously [32]. ChIP DNA was prepared for
HiSeq 2000 Illumina sequencing. Samples were aligned
to human genome, and bioinformatic analysis is fully
described in Additional file 3: Supplementary Methods.
Data access
Data sets are available in the Gene Expression Omnibus
(GEO) database under accession number GSE113289.
Quantitative RT-PCR
Total RNA was extracted from PDXs, MCF10DCIS.com,
and MDA-MB-231 and reverse transcribed using One-
Script Plus Reverse Transcriptase and cDNA Synthesis kit
(abm). Quantitative RT-PCR analyses were done on
Biorad CFX Real-Time PCR System with the fast-SYBR
Green PCR kit as instructed by the manufacturer (Applied
Biosystems). The transcription level of the RPLP0 house-
keeper gene was used as a normalizer. Complete primer
sequences are reported in Additional file 2: Table S4.
Statistical analysis
Data are represented as mean ± SD of biological tripli-
cates (if not diversely indicated in the text). Comparisons
between two or more groups were assessed by using
two-tailed Student’s t test, one-way or two-way ANOVA
followed by the Dunnett post test, or the Bonferroni post
test, as indicated in figure legend. P < 0.05 and lower
were considered significant. For RNA-seq and ChIP-seq
analysis, statistical parameters are indicated in
Additional file 3: Supplementary Methods.
Results
WDR5 promotes breast cancer growth in vivo
In our previous study, we performed a loss of function
shRNA screening in the MCF10DCIS.com (hereafter
MCF10DCIS) BC cell line to identify epigenetic targets
driving tumorigenesis [30]. Since WDR5 was strongly de-
pleted both in the in vivo and in vitro screens and it ranked
as one of the best candidates in sustaining BC growth [30],
we validated its oncogenic role in MCF10DCIS cells. First,
we verified that two single shRNAs (sh1- or sh2-WDR5) in
MCF10DCIS were able to specifically target and silence
WDR5 (Additional file 1: Figure S1A). Then, MCF10DCIS
cells were transduced with the two pooled WDR5 shRNAs
and a corresponding control (shLuc) (Additional file 1: Fig-
ure S1A) and transplanted in NOD/SCID mice to assess
in vivo tumor growth (n = 9 per group). WDR5 silencing
strongly reduced tumor volume in vivo (P < 0.001; Fig. 1a),
confirming its crucial role in sustaining BC growth. Accord-
ingly, WDR5 silencing significantly reduced in vitro cell
proliferation (Fig. 1b), as demonstrated in other tumor
types [13, 15, 16, 18]. Analysis of survival rate among add-
itional groups (n = 5 mice per group) revealed that WDR5
inhibition significantly increased disease-free survival
(P = 0.0052), supporting the prognostic role of WDR5
in BC (Fig. 1c). Conversely, WDR5 overexpression
increased tumor growth in MCF10DCIS cells (Add-
itional file 1: Figure S1B-S1C), paralleling scattered
evidences of correlation of WDR5 overexpression with
tumorigenesis [13, 15, 24–27].
In order to reproduce human cancer in mouse, we cre-
ated a cohort of patient-derived xenografts (PDXs) ob-
tained from liver and lung metastases of BC (MBC)
patients who developed resistance to different lines of
therapy (Additional file 2: Table S1). We focused on LB
and TN subtypes since they are the most aggressive, fre-
quently metastasize to distant organs and few personal-
ized approaches (with exception of hormone therapy)
are available [33]. These PDXs recapitulated the pheno-
typic and molecular features of the tumors (Add-
itional file 2 Table S2) and we used them as surrogate of
patients with BC [29].
Six PDXs were used for the in vivo studies. Two TN
(MBC2 and MBC7) and 4 LB (MBC3, MBC22, MBC18
and MBC26) PDXs were independently transduced with
two shWDR5 in pool or a corresponding control (shLuc)
(Additional file 1: Figure S1D). In parallel, we also used two
TN (SUM149PT and MDAMB468) and two LB (HCC1428
and ZR751) cell lines (Additional file 1: Figure S1E).
The reduction of WDR5 expression significantly inhib-
ited tumor growth in MBC PDXs (Fig. 1d) and in TN
and LB cell lines (Additional file 1: Figure S1F),
suggesting that WDR5 is involved in tumorigenesis
both in ER+ and ER− BC.
WDR5 controls transcriptional changes in breast cancer
A direct transcriptional regulation of tumorigenesis by
WDR5 on its targets has been reported in leukemia and
bladder cancer [13, 25]. To analyze its role in breast can-
cer, we evaluated the transcriptional profile by RNA-seq
of control (shLuc) or shWDR5 cells in two TN and three
LB PDXs (Additional file 2: Table S3; Fig. 2a) and in
MCF10DCIS cell line (Additional file 1: Figure S2A). For
each PDX, we performed pairwise analysis to identify
differentially expressed genes (DEGs). In order to ex-
clude individual specificities, due to the intra- and inter-
tumor heterogeneity of BC patients [29], we considered
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a set of 253 DEGs (161 down- and 92 upregulated) in
common between at least 2 PDXs (Additional file 2:
Table S3). Among these, 99 down- and 40 upregulated
genes were recapitulated in MCF10DCIS (Fig. 2c), iden-
tifying a common regulatory trait upon WDR5 silencing.
Fourteen out of these genes, and WDR5, were randomly
chosen and validated by RT-PCR (Additional file 2:
Table S4) in MCF10DCIS and, those defined as DEGs,
also in two representative PDXs (MBC26 and MBC7)
(Additional file 1: Figure S2B).
In parallel, we assessed H3K4me3 abundance in
MCF10DCIS cells (Additional file 2: Table S3), and we
observed a global reduction of three-methylation intensity
at the promoter level of the expressed genes (± 1500 bp
from transcription start site—TSS) in shWDR5 with
respect to shLuc (P = 3.6E−62) (Additional file 1: Figure
S2C). Specifically, we observed a statistically significant
reduction in H3K4me3 signal at the promoter of the
downregulated (P = 1.3E-38), but not of upregulated genes
(Additional file 1: Figure S2C). Overall, these data
confirmed that WDR5 knockdown reduced target genes
transcription and H3K4 three-methylation, associated
with active and poised TSS, as shown for representative
genes in Additional file 1: Figure S2D.
Fig. 1 WDR5 controls tumorigenesis in breast cancer. a MCF10DCIS cell line was infected to silence WDR5 (shWDR5) or a neutral control (shLuc)
and inoculated in vivo in immunocompromised mice. When tumors of control group reached maximum volume expected, all the mice were
sacrificed to compare effect on tumor growth. Dot plots represent tumor volume in shWDR5 or shLuc MCF10DCIS (n = 9 per group; mean ±
SD—cm3). Statistical significance was determined using an unpaired Student t test (***P < 0.001). b In vitro relative proliferation values of shWDR5
in MCF10DCIS cells are reported with respect to control (shLuc). Statistical significance on n = 3 experiments was determined using an unpaired
Student t test (***P < 0.001). c Percentage of survival of mice belonging to control or shWDR5 groups was calculated. Mice were sacrificed when
each tumor reached maximum volume expected. Differences among groups were calculated by using Log-rank test (n = 5 per group; P = 0.0052).
d Six MBC PDXs were infected to target control (shLuc) and shWDR5. Transduced cells were transplanted in NSG mice. Dot plots represent
volume (mean ± SD—cm3) of three to four tumors per group. Statistical significances were calculated by applying an unpaired Student t test
(**P < 0.01; ***P < 0.001)
Punzi et al. Breast Cancer Research          (2019) 21:123 Page 5 of 18
In order to deeply investigate the involvement of
WDR5 in downstream gene regulation, we performed
Gene Ontology (GO) analysis of DEGs in PDXs as
shown in Fig. 2d. Top-ranking categories included cellu-
lar functions that are known to be regulated by WDR5
(i.e., cell division and G1/S transition) [13, 15–18].
Moreover, EMT, cell migration and wound healing, actin
cytoskeleton rearrangements, and TGFβ regulation
functions were significantly represented after WDR5
knockdown. We analyzed the expression of the most
representative genes in the aforementioned enriched cell
functions and found that they are transcriptionally
regulated, though at different levels, in all PDXs (Fig. 2e).
Typically, genes with a role in G1/S transition or cell
division (i.e., CCND1, BCAT1, UBE2C, DKC1, CCT4,
CCT7) were down-modulated in shWDR5 cells, sup-
porting the role of WDR5 in cell cycle progression. We
focused our attention on functions which are consist-
ently associated with metastasis in human tumors [4, 7]
and possibly open interesting therapeutic applications in
a metastatic setting. Among these, the TGFβ pathway
activation is commonly associated with the malignant
phenotype of cancer cells [34], as well as with metastasis
formation of high-grade BC tumors and BC invasiveness
Fig. 2 WDR5 regulates gene expression in breast cancer. RNA-seq was performed in 5 PDXs upon WDR5 silencing. a Pie charts showed
differentially expressed genes (DEGs) obtained by pairwise analysis in each PDX comparing control (shLuc) and shWDR5 MBC PDXs cells. Genes
were identified as DEGs when the following criteria were met: log2 fold change (FC) ≥ |0.6|, false discovery rate (FDR) < 0.05, and expression > 0.5
RPKM. DEGs in common at least in two PDXs were considered for further analysis. b Heatmap showed normalized expression values after
removing batch effects of 253 DEGs identified as mentioned above (row scaled, z-score). c Corresponding genes which expression was
significantly modified in MCF10DCIS cell line upon WDR5 silencing are reported. Blue and orange colors indicate down- and upregulated genes,
respectively. d Representative Gene Ontology (GO) terms enriched in DEGs of PDXs are shown. For complete list refer to Supplementary Table S3.
e Hierarchical clustering (Euclidean distance, complete linkage) of log2FC of expression levels (expressed as z-score values) of genes involved in
enriched functions due to WDR5 silencing in five different PDXs. Listed genes are included in cell cycle progression (Cell division, G1/S transition),
epithelial-to-mesenchymal transition (EMT), TGFβ1 signaling, wound healing, cell migration, and cell shape (i.e., actin binding and membrane raft)
(see text). Log2FC of each gene was calculated as ratio of gene expression of shWDR5 to shLuc (control) PDX samples (done in triplicate)
Punzi et al. Breast Cancer Research          (2019) 21:123 Page 6 of 18
[35]. Indeed, TGFβ1 targets (i.e., FURIN, LTBP2,
PARD6A, GCNT2, TGFβR2), as well as other EMT re-
gulators (i.e., SNAI2, ZEB1/2, and TWIST1) were down-
modulated in the majority of the shWDR5 PDXs
(Fig. 2e). Analogously, genes involved in wound healing
and cell migration (i.e., SERPINE1, HMGCR, IGFBP5,
and S100A14) or reported as prognostic factors in
breast, ovarian, gastric, and lung cancers (i.e., MAPRE1,
HSPA1B, and PPME1) [36–38] were negatively modu-
lated. Instead, genes responsible of actin remodeling (i.e.,
CFL2, CORO1C, FSCN1) and membrane raft (i.e., MAL,
BIRC3, PLLP, TNF) were upregulated in WDR5 knock-
down condition due to the increased cell polarization and
cell-cell adhesion (Fig. 2e). Representative genes with a
role in EMT were validated by RT-PCR (dots highlighted
in blue), as reported in Additional file 1: Figure S2B.
To extend this observation to a larger cohort of BC
patients, WDR5-transcriptionally regulated genes
highlighted in Fig. 2e were compared with publicly avail-
able gene expression data in cBioportal for Cancer Gen-
omics (https://www.cbioportal.org). Expression analysis
showed that the majority of WDR5 targets were overex-
pressed (z-score ≥ + 2) (n = 1093 breast cancer patients)
(Additional file 1: Figure S3A). Then, we evaluated the
expression pattern of these genes in comparison with
WDR5 and we found a significant co-overexpression of
WDR5 with genes associated with EMT and unfavorable
prognosis, such as GCNT2, PPME1, MAPRE1, SNAI2,
ZEB2, and S100A14 [39, 40], and tumor growth (UBE2C
[41]) (Fisher’s exact test; P ≤ 0.05) (Additional file 1:
Figure S3B). Collectively, these observations suggest that,
as proposed in our model, WDR5 and its targets can be
dysregulated in BC patients, likely driving tumorigenic
events. Finally, these data confirm that WDR5 regulates
a large set of genes affecting both proliferation and EMT
in BC.
WDR5 expression is crucial to sustain the mesenchymal
phenotype in breast cancer
Among different hypothesis taking into consideration
inherited or acquired traits leading to metastatic events,
a large body of literature sustains that the coordinated
transcriptional control of cell adhesion, cell shape, mi-
gration, and EMT is required to support both invasion
and metastasis [2, 4, 10]. We speculate that WDR5 may
exert this governance in BC. The adhesion assay per-
formed in control- and shWDR5-MCF10DCIS cells on a
panel of extracellular matrices (collagen, laminin, fibro-
nectin, matrigel) showed that cell adhesion was in-
creased in shWDR5 cells both in terms of cell number
and cell area (Fig. 3a and Additional file 1: Figure S4A),
thus suggesting a tighter cell anchoring to the matrix.
Filamentous actin (F-actin), detected by immunofluores-
cence (IF), was assembled into stress fibers in
MCF10DCIS control cells, while in shWDR5 cells pre-
dominantly organized in cortical bundles tightly associ-
ated with cell-cell adhesions (Fig. 3b), more reminiscent
of an epithelial-like phenotype. In order to properly
analyze the effects of WDR5 on live cell motility, we per-
formed an in vitro time-lapse random migration assay in
MCF10DCIS. WDR5 silencing induced a significant re-
duction of cell motility with respect to the control
(shLuc) (Fig. 3c), quantified as displacement (μm) in the
box plots (about 40%) (***: p value < 0.001) (Fig. 3d),
suggesting that WDR5 regulates breast cancer cell motil-
ity, as previously observed in other systems [42]. Reduc-
tion of motility was also associated with depletion of
FBS-directed migration in MCF10DCIS and PDX cells
(Fig. 3e and Additional file 1: Figure S4B), as well as in-
hibition of wound healing capacity (Additional file 1:
Figure S4C) due to WDR5 silencing.
We then characterized the response to WDR5 silen-
cing in terms of mesenchymal and epithelial marker
regulation. CDH2, SNAI1, and SNAI2 protein levels
were reduced, as shown by IF (Fig. 3f) or western blot
(Fig. 3g), although Vimentin (VIM) and Cadherin 1
(CDH1) were only partially affected by WDR5 knock-
down. We also evaluated the membranous (MEB), cyto-
plasmic (CEB), and total protein levels of CDH1 in
WDR5 knocked -down cells (Fig. 3h). Following cellular
fractionation, CDH1 staining was detected only in MEB,
without significant differences in total protein levels be-
tween shLuc and shWDR5 cells. These data indicate that
CDH1 levels are fully ascribable to the membranous
component and that CDH1 is not primarily involved in
EMT reversion due to WDR5 silencing. Conversely,
overexpression of WDR5 caused changes in cell morph-
ology, leading to an elongated spindle shape of the cells
(Additional file 1: Figure S4D), accompanied by changes
in gene expression reflecting the mesenchymal scenario
(Additional file 1: Figure S4E). These observations
suggest that WDR5 is accountable of maintaining an
aggressive and metastatic phenotype and that its inhi-
bition determines a partial mesenchymal reversion, thus
driving cells toward an epithelial trait.
WDR5 induces breast cancer metastasis
In order to correlate WDR5 expression and the meta-
static process, by using a second independent data set
[31], we evaluated WDR5 expression and metastasis-free
survival (MFS) association in a cohort of BC patients
(n = 295; WDR5 high expression = 148; WDR5 low ex-
pression = 147). Higher WDR5 expression was associated
with worse MFS (Fig. 4a), confirming the prognostic role
of WDR5 in the metastatic event. Moreover, MFS ana-
lysis adjusted for ER and therapeutic (endocrine or
chemotherapy) status showed that patient outcome was
independent of these factors (Additional file 1: Figure
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Fig. 3 WDR5 silencing inhibits EMT. a Adhesion to a panel of substrates (collagen—CL, laminin—LM, fibronectin—FN, matrigel—MG) in shLuc or
shWDR5 MCF10DCIS cells was considered. Cells were stained by crystal violet and adhesion property was calculated by ImageJ and expressed as
ratio of relative cells area of shWDR5 versus shLuc in biological triplicates. Statistical significances among areas were calculated by applying an
unpaired Student t test (***P < 0.001). b Morphological changes were evaluated by actin cytoskeleton staining of F-actin in MCF10DCIS cells due
to WDR5 silencing by immunofluorescence technique (n = 3). Images show F-actin (green), DAPI (blue), and merged staining of shLuc and
shWDR5 cells. c Trajectory plots were obtained by in vitro random migration assay, performed in MCF10DCIS cells. ShLuc and shWDR5 conditions
were analyzed by time-lapse microscopy (n = 180 cells in shLuc and n = 209 cells in shWDR5) and data acquired every 10 min over a 24-h time
course. d Box plot represents the displacement (μm) of cells as accumulated distance. Significant differences among groups were analyzed by an
unpaired Student t test (***P < 0.001). e Effect of WDR5 silencing was evaluated in terms of in vitro FBS-directed cell migration. Images were
compared to quantify the percentage of cell migration (mean ± SD; n = 3). Significant differences among groups were calculated by applying an
unpaired Student t test (***P < 0.001). f–h Effect of WDR5 silencing on the expression of EMT markers were evaluated by immunofluorescence (f)
or western blot (g) in MCF10DCIS cells. Vimentin (VIM), N-Cadherin (CDH2), and SNAI1 and SNAI2 total protein expression was detected in shLuc
and shWDR5 cells. Tubulin (Tub) or Vinculin (Vin) were used as normalizers, according to the molecular weight of proteins analyzed. h E-Cadherin
(CDH1) level was detected by western blot in membranous (MEB), cytoplasmic (CEB), and total protein lysates. GAPDH was used to assess the
amount of total protein lysates in the two samples and as positive control of CEB
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Fig. 4 WDR5 silencing significantly reduced breast cancer metastasis. a) Metastasis free survival in breast cancer patients (n = 295) was calculated
in WDR5-low and WDR5-high groups divided at median of gene expression. Statistic comparison was performed using log-rank test. b)
Representative IHC staining of WDR5 expression in normal breast tissues (n = 11) and Metastatic Breast Cancer (MBC) PDXs (n = 8) is reported.
Scale bar 100 μm. Box plots represent WDR5 expression quantified by using Fiji tools for DAB positivity. Statistical significance was determined
using an unpaired Student t test (***: P < 0.001). c) Effect of WDR5 silencing on metastasis formation in vivo in MDA-MB-231. Luciferase-
transduced cells were infected to silence WDR5 or a control vector (SCR) and then transplanted in NSG mice (n = 12 per group). Metastases at
distant organs were detected by using bioluminescence technique in vivo after resection of primary tumors as reported in Fig. d) Dot plots
represent luminescence expressed in radiance of photons detected at metastatic sites in SCR and shWDR5 groups. Values were calculated by IVIS
Illumina Software and compared by applying an unpaired Student t test (P = 0.0010). e) Differences among SCR and shWDR5 groups in terms of
percentage of survival were calculated by using Log-rank test (n = 7; P = 0.0003). f) RT-PCR was performed in SCR and shWDR5 MDA-MB-231 cells.
Bars represent Log2FC of ΔΔCT values of shWDR5 to SCR of WDR5-target genes, classified on the basis of their biological functions
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S5A). In addition, we compared WDR5 protein levels of
normal breast with MBC PDX tissues by IHC (Fig. 4b)
and of MCF10DCIS and MDA-MB-231 BC cell lines
with a non-transformed counterpart, MCF10A, by west-
ern blot (Additional file 1: Figure S5B). In both cases,
BC samples, and remarkably the metastatic ones, showed
increased WDR5 levels with respect to normal/non-
transformed ones, thus paralleling observation on meta-
static BC patients. In order to validate this observation,
we used MDA-MB-231 cells that are able to maintain
the metastatic tropism and represent a successful model
for studying BC metastasis. We compared the metastatic
ability of SCR and shWDR5 MDA-MB-231 cells by per-
forming a functional in vivo assay that recapitulated the
phases of metastatic cascade from primary tumor to me-
tastasis formation. Cells were transplanted in the fourth
mammary gland of NSG mice (n = 12); tumors were
resected at the same volume, both in control and
WDR5-silenced groups; and metastases at distant organs
were detected (Additional file 1: Figure S5C). MDA-MB-
231 metastasized to lung and axillary lymph nodes in
SCR (Fig. 4c, upper panel), while WDR5 silencing totally
inhibited (9/12), or significantly reduced (3/12), the
number and size of the metastatic foci (Fig. 4c, lower
panel), as confirmed by the highly significant difference
in luminescence (expressed as radiance) among the two
groups (P = 0.001; Fig. 4d). In addition, mice in which
WDR5 was silenced showed a significant survival (P =
0.0003) with respect to the control (Fig. 4e). Corre-
sponding to the in vivo results, WDR5 silencing led to a
consistent reduction of MDA-MB-231 in vitro FBS-
directed cell migration (Additional file 1: Figure S5D),
wound healing (Additional file 1: Figure S5E), and ran-
dom migration assays (Additional file 1: Figure S5F),
confirming that WDR5 impacts on the ability of BC cells
to migrate and metastasize to distant organs and that its
expression is predictive of metastatic disease. Then, we
confirmed by RT-PCR that the expression of WDR5-
downstream genes involved in EMT and metastatic
phenotype was also modulated in MDA-MB-231 upon
WDR5 silencing (Fig. 4f), thus suggesting that WDR5 in-
hibition may be a useful approach to induce the rever-
sion of the mesenchymal trait in a metastatic setting.
WDR5 regulates TGFβ1 activation in breast cancer
As suggested by the analysis on RNA-seq profile, WDR5
transcriptionally modulates genes involved in the EMT.
In order to deeply investigate the direct interaction of
WDR5 and its targets, we first performed an upstream
analysis of the DEGs in PDXs and in MCF10DCIS cells.
Ingenuity pathway analysis (IPA) confirmed the putative
involvement of genes that regulate EMT (HDAC3,
ERBB2, SMAD7) [8, 28, 43] or drive tumor progression
and metastatic dissemination (i.e., TP53, TNF, ESR1,
HGF, PI3K) in BC. Interestingly, TGFβ1 resulted as one
of the top-ranked upstream genes among PDXs and
MCF10DCIS (Fig. 5a). Then, chromatin immunoprecipi-
tation (ChIP) and sequencing was performed to analyze
the genome-wide WDR5 occupancy in MCF10DCIS
cells (Additional file 2: Table S3). We found that around
80% (4413/5794) of the WDR5 peaks were located in
close proximity to the TSS (± 3000 bp), confirming that
WDR5 regulates its targets mainly at the promoter level.
As expected, some already known interactors of WDR5
(i.e., TWIST1, ERBB2, LYN, and RBM22) [14, 22, 25]
are regulated on their promoters (Table S3), thus valid-
ating our analysis. When RNA-seq and WDR5 peaks
were intersected, we found 364 WDR5 peaks overlap-
ping with downregulated and 189 corresponding with
upregulated genes (Additional file 1: Figure S6A).
Among these, WDR5 bound TGFβ1 promoter, as con-
firmed by the quantitative chromatin immunoprecipita-
tion (qChIP) performed in shLuc and shWDR5
MCF10DCIS cells (Fig. 5b). Indeed, WDR5 knockdown
inhibited TGFβ1 transcription in MCF10DCIS (Fig. 6b
and Fig. 5c), as well as in MDA-MB-231 and in diverse
LB and TN BC cell lines (Fig. 5c). Since TGFβ1 is a po-
tent inducer of the EMT in mammary cells [35], we hy-
pothesized that WDR5 may regulate TGFβ1 to
orchestrate the observed phenotype. In order to confirm
this observation, we silenced TGFβ1 (shTGFβ1) in pres-
ence (+) or absence (−) of WDR5 overexpression in
MCF10DCIS cells. First, we observed that TGFβ1 knock-
down significantly reduced cell migration (Fig. 5d) and
wound healing (Additional file 1: Figure S6C), as shown
with WDR5 silencing. Strikingly, shTGFβ1 abrogated
MCF10DCIS migration induced by WDR5 overexpres-
sion (Fig. 5d), that in turn increased TGFβ1 mRNA
levels (Fig. 5e). We also evaluated in the same conditions
the mesenchymal markers known to be regulated by
WDR5 (Fig. 3f–h), and we confirmed that TGFβ1 silen-
cing was able to interfere with the WDR5-induced mes-
enchymal phenotype, by inhibiting EMT genes at the
RNA (RT-PCR, Fig. 5f) and protein (IF, Fig. 5g) levels.
Overall, these data confirm that TGFβ1 is responsible, at
least in part, for WDR5 phenotype and that the inhi-
bition of the WDR5-TGFβ1 axis could be envisioned as
a therapeutic strategy to inhibit EMT.
Drug targeting of WDR5-TGFβ1 axis reduces breast
cancer aggressiveness
WDR5 inhibitor OICR-9429 has been successfully used
to reduce tumorigenesis of leukemia, pancreatic cancer,
and neuroblastoma [15, 17, 44]. Moreover, recently, an
in vivo approach by monobody against WDR5 has been
tested in a leukemia background [45]. In addition, the
inhibitors of TGFβ1 receptors have been proposed as
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Fig. 5 WDR5 regulates TGFβ1 in breast cancer. a Ingenuity pathway analysis was used for upstream pathway evaluation. Representative regulators of
DEGs in PDXs and MCF10DCIS are shown. For complete list, refer to Supplementary Table S3. TGFβ1 is reported as one of the most significative upstream
regulators in all samples. b Quantitative chromatin immunoprecipitation (qChIP) was used to analyze binding of WDR5 to TGFβ1 promoter in MCF10DCIS
cells. qChIP was performed on shLuc and shWDR5 cells and values expressed as percentage of input chromatin (mean ± SD; n= 2; *P< 0.05). c RT-PCR was
performed to evaluate TGFβ1 mRNA level reduction upon WDR5 silencing in MCF10DCIS, MDA-MB-231, and other BC cell lines (2 TN—SUM149PT and
MDAMB468—and 2 LB—ZR751 and HCC1428). Statistical significance among shLuc and shWDR5 groups was calculated by applying a Student t test
(*P< 0.05; **P< 0.01; ***P< 0.001). d–g MCF10DCIS cells were infected to silence TGFβ1 (shTGFβ1) in presence (+) or absence (−) of WDR5 overexpression.
d Relative migration was evaluated in the indicated conditions and representative images reported. Statistical significance among groups was calculated
by applying one-way ANOVA followed by the Bonferroni post test (*P< 0.05; **P< 0.01; ***P< 0.001). e TGFβ1 mRNA levels were evaluated by RT-PCR in
presence (+) or absence (−) of WDR5 overexpression. Statistical significance among groups was calculated by applying an unpaired Student t test
(*P< 0.05; **P< 0.01; ***P< 0.001). f, g EMT markers were evaluated by RT-PCR (f) and immunofluorescence (IF) techniques (g) in the indicated conditions.
Statistical significance among groups was calculated by applying an unpaired Student t test (*P< 0.05; **P< 0.01). Nuclei are stained in blue (DAPI), cell
morphology assessed by tubulin staining (in green), VIM, CDH2, SNAI1, and SNAI2 are labeled in red (× 40 magnification)
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Fig. 6 (See legend on next page.)
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new anti-metastatic therapy [46], such as galunisertib
(LY2157299), that has entered phase II/III clinical trials
in pancreatic cancer, glioblastoma, hepatocellular carcin-
oma, and myelodysplastic syndrome [47].
We first used MDA-MB-231 and MCF10DCIS to test
the efficacy of OICR-9429 in regulating cell migration.
OICR-9429 significantly reduced BC cell line migration
in a dose-dependent manner (Fig. 6a and Additional file 1:
S7A), while it did not affect the migration of the
MCF10A non-transformed cells (Additional file 1: Figure
S7B), suggesting that WDR5 inhibition may exert spe-
cific effects on tumor cells. We confirmed that OICR-
9429 treatment (20 μM), as WDR5 silencing, resulted in
TGFβ1 mRNA level reduction in MDA-MB-231 (Fig. 6b)
and MCF10DCIS (Additional file 1: Figure S7C). Then,
we confirmed that galunisertib (10 μM) significantly re-
duced MDA-MB-231 and MCF10DCIS cell migration
(Fig. 6c and Additional file 1: Figure S7D). In MDA-MB-
231 cells, drug administration exerted an analogous ef-
fect on the most relevant EMT markers, by reducing
CDH2 and SNAI1, without affecting VIM, in terms of
relative mRNA levels verified by RT-PCR (Fig. 6d) and
protein expression by IF (Fig. 6e). In MCF10DCIS,
CDH2 and SNAI2 were significantly reduced due to
both treatments (Additional file 1: Figure S7E), while
SNAI1, although down-modulated, reached significance
only in galunisertib treatment. Moreover, drug adminis-
tration exerted a drastic change of MCF10DCIS cell
shape that assumes a more cobblestone-like morphology
with epithelial features, as shown by tubulin staining
(Additional file 1: Figure S7F).
Finally, in two different PDXs (one LB: MBC26 and one
TN: MBC2), OICR-9429 administration (20 μM) signifi-
cantly reduced TGFβ1 mRNA levels (Fig. 6f), migratory
potential (Fig. 6g), and expression of mesenchymal genes
(Fig. 6h). These effects were recapitulated, at least in part,
by galunisertib administration (10 μM). In MBC26, drug
treatment caused a slight increase in SNAI2 expression
that can be justified by the fact that EMT and its reversion
may generate a mixed population of cells, possibly ac-
counting for a partial EMT phenotype. SNAI1 is anyway
sufficient to ensure EMT, as reported elsewhere in BC
cells [48]. Overall, these data confirm that drugs targeting
WDR5-TGFβ1 axis significantly inhibit EMT in BC. It can
therefore be speculated that, by suppressing mesenchymal
features of cancer cells, these drugs may have a strong
potential of reducing BC metastasis.
WDR5-TGFβ1 inhibition restores drug sensitivity
The transition from a mesenchymal to an epithelial state
with drug treatment can be used to enhance lethality
and eradicate epithelial cells, as well as a strategy to
sensitize cells to chemotherapy [3]. We used MBC2 and
MBC26 PDXs to test the effect of WDR5 inhibition on
lethality in combination with paclitaxel (PTX), indicated
for first-line therapy in TN breast cancer and later-line
therapy in ER+ metastatic breast cancer [49].
As previously shown, MBC2 and MBC26 PDXs showed
resistance to different doses of PTX [29] (Fig. 7a). Strik-
ingly, OICR-9429 or galunisertib, that did not reduce pro-
liferation per se in both PDXs (Additional file 1: Figure
S8A), sensitized cells to PTX reducing cell viability in
combinatorial treatments (Fig. 7a). As observed in MDA-
MB-231 cells, administration of OICR-9429 or galuniser-
tib and PTX, at the half maximal inhibitory concentration
(10 nM), additionally reduced about 10–15% cell viability
(Fig. 7b), marked by cleavage of PARP, increased DNA
damage (through the phosphorylation of H2AX), and
slight reduction of PCNA (Additional file 1: Figure S8B).
Since PTX treatment results in the disruption of the
microtubule dynamics, which is essential during cell div-
ision, we performed analysis of the bromodeoxyuridine
(BrDu) and propidium iodide (PI) content in MDA-MB-
231 in the aforementioned conditions. MDA-MB-231 cells
(See figure on previous page.)
Fig. 6 WDR5-TGFβ1 inhibition reduces cell migration and EMT gene expression in breast cancer. a Effect of WDR5 inhibitor OICR-9429 at
increasing concentrations (1 μM, 5 μM, 10 μM, 20 μM, 3 days of treatment) was evaluated in MDA-MB-231 cell line. Cells were plated on transwells
to test in vitro cell migration, stained with crystal violet, and quantified using ImageJ analysis. Histograms represent relative cell migration
expressed as mean ± SD of a biological triplicate. Differences among groups were calculated by applying one-way ANOVA and Dunnett post test
(*P < 0.05; ***P < 0.001). b TGFβ1 mRNA levels (mean ± SD of n = 3 experiments) were evaluated by RT-PCR upon OICR-9429 treatment (20 μM) in
MDA-MB-231 cells. Statistical differences were calculated by applying a Student t test (*P < 0.05). c MDA-MB-231 cells were treated with OICR-
9429 (20 μM) and galunisertib (10 μM—TGFβ1 inhibitor) for 3 days and cells were plated on transwells for the evaluation of in vitro cell migration.
Differences among groups were evaluated by applying one-way ANOVA and Dunnett post test (***P < 0.001). d, e VIM, CDH2, SNAI1, and SNAI2
expression was evaluated by RT-PCR (d) and immunofluorescence (e) upon OICR-9429 (20 μM) and galunisertib (10 μM) treatments. Differences in
mRNA levels among groups were evaluated by applying an unpaired Student t test (*P < 0.05; ***P < 0.001). For immunofluorescence, DAPI (in
blue) was used for nuclei staining and tubulin (in green) for cell morphology staining. VIM, CDH2, SNAI1, and SNAI2 are labeled in red. f Effects of
OICR-9429 (20 μM) on TGFβ1 mRNA levels were evaluated in one TN (MBC2) and one LB (MBC26) PDXs. Statistical differences among groups
were calculated by applying a Student t test (**P < 0.01; ***P < 0.001). g Effects of OICR-9429 (20 μM) and galunisertib (10 μM) were evaluated in
terms of in vitro cell migration after 3 days of treatment in MBC2 and MBC26 PDX cells (mean ± SD of n = 3 experiments). Differences among
groups were evaluated by applying one-way ANOVA and Dunnett post test (**P < 0.01; ***P < 0.001). h mRNA levels of VIM, CDH2, SNAI1, and
SNAI2 were evaluated by RT-PCR due to aforementioned treatments in MBC2 and MBC26 PDX cells. Statistical significances among groups were
calculated by applying a Student t test (*P < 0.05; **P < 0.01; ***P < 0.001)
Punzi et al. Breast Cancer Research          (2019) 21:123 Page 13 of 18
Fig. 7 WDR5 inhibitor sensitizes breast cancer cells to paclitaxel. a One TN (MBC2) and one LB (MBC26) PDXs were treated for 3 days with diverse
concentrations of paclitaxel (PTX) (1 nM, 5 nM, and 10 nM) alone or in combination with OICR-9429 (20 μM) or galunisertib (10 μM). Cell viability is
reported as ratio of the control group (vehicle). Differences among indicated concentrations were calculated by applying a Student t test
(mean ± SD of n = 3 experiments; *P < 0.05; **P < 0.01). Asterisk colors are associated with corresponding treatment. b MDA-MB-231 cells were
treated for 3 days with PTX (10 nM) upon OICR-9429 (20 μM) or galunisertib (10 μM) treatments. Cell viability of each condition was expressed as
ratio to the control group (vehicle) and significant differences among groups calculated by an unpaired Student t test (mean ± SD of n = 3
biological replicas; ***P < 0.001). c MDA-MB-231 cells were treated as above and analyzed by flow cytometry for bromodeoxyhuridine (BrDU) and
propidium iodide (PI) content. Percentage (%) of cell population in each phase of cell cycle (G0/G1, S, S-not cycling and G2/M) is represented for
each condition. Statistical significance was calculated by applying two-way ANOVA followed by the Bonferroni post test for multiple comparisons
(*P < 0.05; **P < 0.01; ***P < 0.001). Colors of the asterisks are associated with the phase of the cell cycle in which the differences were detected.
d Schematic representation of WDR5 mechanism of action in breast cancer for the maintenance of cells hovering from mesenchymal to epithelial-like
phenotype. TGFβ1 is directly regulated by WDR5 and largely participates to this governance so effectively that inhibition of WDR5-TGFβ1 axis switches
cell state from metastable to low metastatic and reduces breast cancer progression
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treated with PTX were unable to regularly proceed
through the cell cycle, as suggested by an increase of the
percentage of cells in the G2-M phase, and a concomitant
reduction of S and G1 phases. Although OICR-9429 or
galunisertib did not alter cell cycle progression, the com-
binatorial administration of PTX further increased the
block of the cell cycle (Fig. 7c and Additional file 1: Figure
S8C), thus suggesting that inhibition of WDR5 or TGFβ1
signaling can potentiate the activity of chemotherapy. In
addition, both in PTX and combinatorial treatments, a
not-cycling S phase population was detected, confirming
that a substantial percentage of the cells was not prolifer-
ating (Fig. 7c and Additional file 1: Figure S8C).
Overall, these data indicate that inhibiting WDR5, or
its target TGFβ1, is an effective strategy to sensitize
drug-resistant cells to chemotherapy, as found for ZEB1,
TWIST, and SNAIL [50–52], thus suggesting a rational
combination to restrict BC progression.
Discussion
It is largely recognized that the dysregulation of chromatin
remodelers is often associated with, or drives the develop-
ment of, human cancers [10]. Despite this notion, the mo-
lecular basis of such connection is still a matter of debate.
Moreover, epigenetic modifications may underlie cancer-
specific phenotypes and represent molecular vulnerabil-
ities that can be targeted in cancer therapy.
In this study, we report that WDR5, the core subunit of
methyltransferase complex, is an essential gene for breast
cancer progression since its inhibition is associated with
reduction of tumorigenesis and metastasis. We demon-
strate that loss of WDR5 transcriptionally represses its tar-
get genes and uncouple TGFβ1 pathway and EMT, thus
inducing a switch from a mesenchymal-like phenotype to-
ward an epithelial status (Fig. 7d) in BC cells. Then, we
suggest WDR5 inhibition as a therapeutic strategy to hit
the EMT network, reduce metastasis, and sensitize breast
cancer cells to chemotherapy.
Consistent with the prognostic role of WDR5 [24–27],
we associated its expression with breast cancer progression
and aggressiveness, by making use of a panel of cell lines
and PDX models of metastatic tumors, the latter repre-
senting patients resistant to different lines of therapy. In
agreement with this observation, we showed that WDR5
inhibition was effective in reducing tumor growth in all LB
and TN breast cancers samples, independently by ER sta-
tus or therapies. In addition, WDR5 loss reduced metasta-
sis dissemination of BC cells in vivo. The ability of tumor
cells to metastasize has been frequently correlated with the
EMT, since the transition from a well-differentiated epi-
thelial phenotype to an invasive mesenchymal state, whose
regulation is under transcriptional and post-transcriptional
control, may enhance cell motility and invasiveness [4, 7].
Previous works also suggest that WDR5 plays a critical
role in the regulation of tumor cell migration, as well as of
invasion in a zebrafish transplantation model [9, 28, 42,
53], and in the control of metastasis formation by inducing
EMT in various cancers [21–23]. We speculated that
WDR5 could induce EMT in breast cancer and that its in-
hibition could reverse the mesenchymal phenotype, con-
sistent with known plasticity of this cellular program
whereby cells switch from the mesenchymal to the epithe-
lial states and back [2]. By employing gene expression pro-
filing upon WDR5 inhibition in breast cancer, we found
that WDR5 transcriptionally regulates gene signatures,
typically involved either in proliferation and cell cycle, or
in metastasis, EMT, and their correlated functions. Thus,
this governance can also be ascribed to epigenetic regula-
tion, since active histone mark (H3K4me3) was found
significantly modified at the promoter of differentially
expressed genes. We have demonstrated that, beyond the
effects on proliferation, WDR5 inhibition drives cells to a
partial epithelial status by reducing expression of the main
mesenchymal genes and cell motility and migration, and
partly restoring the typical features of epithelial-like cells
(i.e., polarization and cell-cell adhesion). Our genome-
wide binding site analysis showed that WDR5 binds to the
TGFβ1 promoter. TGFβ1 signaling and EMT are strictly
interconnected in cancer since TGFβ1 controls cell motil-
ity and the mesenchymal properties of the cells [7, 54]. We
speculated that a similar mechanism is in place in breast
cancer and is due to WDR5 regulation, which has a prom-
inent role per se in EMT and metastasis [17, 18, 23], as
well as through TGFβ1. We demonstrated that WDR5 in-
hibition reduced TGFβ1 levels and that TGFβ1 silencing,
in turn, is capable of abrogating WDR5-dependent migra-
tion, thus confirming that TGFβ1 is crucial (at least in
part) in leading WDR5-dependent mesenchymal pheno-
type. This observation takes into consideration endogen-
ous activation of TGFβ1 and can complement that one
reported by Chen and colleagues contemplating TGFβ1
exogenous stimulation [9]. Moreover, the role of TGFβ1 in
driving EMT has been predominantly reported for basal-
like cells, largely superimposable to the cells of the TN
subtype [55]. Our observations suggest that also luminal-
like breast cancer is poised to respond to EMT signals and
that, concordantly, its inhibition can be a useful method to
suppress mesenchymal properties associated to metastasis
of cancer cells.
Recently, therapeutic investigations have shown in-
creased interest in the EMT estimation. In fact, diverse
clinical trials have included the evaluation of biomarkers
of EMT as translational endpoint and diagnostic tool for
the detection of circulating tumor cells for advanced
breast cancer (Clinicaltrials.gov). Considering the exist-
ence of the EMT gradients, evidences indicate that the
efficacy of mesenchymal reversal may be cancer type
dependent and should be based on a specific therapeutic
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window to abolish metastasis and enhance drug sensitiv-
ity, thus disadvantaging colonization [2]. Although cell
differentiation is considered an attractive therapeutic ap-
proach to reverse the mesenchymal phenotype, drug dis-
covery platform for EMT switch is still limited. Here, we
provide evidences that the WDR5 inhibitor OICR-9429
is able to sensitize breast cancer cells to chemotherapy
by reversing the mesenchymal phenotype, overcoming
drug resistance, as similarly reported for other epigenetic
inhibitors undergoing clinical trials (i.e., Mocetinostat)
[3]. Indeed, WDR5 inhibitor sensitizes cells to paclitaxel,
revealing a promising combination to eradicate tumor
cells in chemo-resistant breast cancer patients.
Conclusions
In conclusion, we have demonstrated that WDR5 cou-
ples EMT and metastatic progression in breast cancer.
The inhibitory effects on tumorigenesis and progression
due to WDR5 block in PDXs, derived from metastatic
patients resistant to therapies, are encouraging for fur-
ther clinical investigations and suggest a new therapeutic
chance for these patients. Finally, our data support
WDR5 inhibition as a novel strategy to reverse mesen-
chymal features and sensitize cancer cells to chemotherapy,
thus restricting tumor metastasis in breast cancer.
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